

**Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)**

Market Report | 2022-09-26 | 150 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

The MEA human papillomavirus (HPV) vaccine market is expected to grow from US\$ 82.91 million in 2022 to US\$ 100.86 million by 2028; it is estimated to grow at a CAGR of 3.3% from 2022 to 2028.

Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the region must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer. In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. Many countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer, initiated the Gavi HPV vaccine program. All these initiatives are aiding the HPV vaccines market substantially across the region.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA human papillomavirus (HPV) vaccine market. The MEA human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

## MEA Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)

### MEA Human Papillomavirus (HPV) Vaccine Market Segmentation

The MEA human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the MEA human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022. Based on dosage, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022. Based on age, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022. Based on application, the MEA human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022. Based on end user, the MEA human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022. Based on country, the MEA human papillomavirus (HPV) vaccine market has been categorized into Saudi Arabia, South Africa, the UAE, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of MEA. Saudi Arabia would dominate the market in 2022.

GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; and Walvax Biotechnology Co., Ltd. are among the leading companies in the MEA human papillomavirus (HPV) vaccine market.

### Table of Contents:

#### TABLE OF CONTENTS

1. Introduction
  - 1.1 Study Scope
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 MEA Human Papillomavirus (HPV) Vaccines Market - By Type
    - 1.3.2 MEA Human Papillomavirus (HPV) Vaccines Market - By Dosage
    - 1.3.3 MEA Human Papillomavirus (HPV) Vaccines Market - By Age
    - 1.3.4 MEA Human Papillomavirus (HPV) Vaccines Market - By Application
    - 1.3.5 MEA Human Papillomavirus (HPV) Vaccines Market - By Distribution Channel
    - 1.3.6 MEA Human Papillomavirus (HPV) Vaccines Market - By Country
2. Key Takeaways
3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
4. MEA Human Papillomavirus (HPV) Vaccine Market - Market Landscape
  - 4.1 Overview
  - 4.2 MEA PEST Analysis
  - 4.3 Experts Opinion
5. MEA Human Papillomavirus (HPV) Vaccine Market - Key Market Dynamics

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.1 Market Drivers
  - 5.1.1 Increase in Prevalence of HPV Associated Diseases
  - 5.1.2 Initiatives Taken by Health Organizations
- 5.2 Market Restraints
  - 5.2.1 High Cost of HPV Vaccines
- 5.3 Future Trends
  - 5.3.1 Advancements in HPV Diagnostics Tests
- 5.4 Impact Analysis
- 6. Human Papillomavirus (HPV) Vaccine Market- MEA Analysis
  - 6.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis
- 7. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Type
  - 7.1 Overview
  - 7.2 By Type: Market Revenue and Forecast Analysis (US\$ Million)
  - 7.3 9-valent HPV vaccine
    - 7.3.1 Overview
    - 7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 7.4 Quadrivalent HPV vaccine
    - 7.4.1 Overview
    - 7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 7.5 Bivalent HPV Vaccine
    - 7.5.1 Overview
    - 7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
- 8. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
  - 8.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
  - 8.2 2 Dose
    - 8.2.1 Overview
    - 8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 8.3 3 Dose
    - 8.3.1 Overview
    - 8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
- 9. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
  - 9.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
  - 9.2 9 to 14 Years
    - 9.2.1 Overview
    - 9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.3 to 45 Years
    - 9.3.1 Overview
    - 9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
- 10. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
  - 10.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
  - 10.2 HPV-attributable Cancer
    - 10.2.1 Overview
    - 10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 10.3 Genital Warts
    - 10.3.1 Overview
    - 10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
- 11. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By End User

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.1 Overview
- 11.2 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
- 11.3 Doctor Office
  - 11.3.1 Overview
  - 11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US\$ Million)
- 11.4 Community Health Clinics
  - 11.4.1 Overview
  - 11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US\$ Million)
- 11.5 School-based Health Centers
  - 11.5.1 Overview
  - 11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US\$ Million)
- 11.6 Health Departments
  - 11.6.1 Overview
  - 11.6.2 Health Departments Market Revenue and Forecast to 2028 (US\$ Million)
- 11.7 Hospitals
  - 11.7.1 Overview
  - 11.7.2 Hospitals Market Revenue and Forecast to 2028 (US\$ Million)
- 11.8 Others
  - 11.8.1 Overview
  - 11.8.2 Others Market Revenue and Forecast to 2028 (US\$ Million)
- 12. MEA Human Papillomavirus (HPV) Vaccine Market - Country Analysis
  - 12.1 Overview
    - 12.1.1 MEA: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)
      - 12.1.1.1 UAE: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
        - 12.1.1.1.1 Overview
          - 12.1.1.1.2 UAE: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
          - 12.1.1.1.3 UAE: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
          - 12.1.1.1.4 UAE: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
          - 12.1.1.1.5 UAE: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
          - 12.1.1.1.6 UAE: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
          - 12.1.1.1.7 UAE: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
        - 12.1.1.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
          - 12.1.1.2.1 Overview
            - 12.1.1.2.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
            - 12.1.1.2.3 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
            - 12.1.1.2.4 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
            - 12.1.1.2.5 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
            - 12.1.1.2.6 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
            - 12.1.1.2.7 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
        - 12.1.1.3 South Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
          - 12.1.1.3.1 Overview
            - 12.1.1.3.2 South Africa: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
            - 12.1.1.3.3 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
            - 12.1.1.3.4 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
            - 12.1.1.3.5 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
            - 12.1.1.3.6 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
            - 12.1.1.3.7 South Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.1.1.4 Iran: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.4.1 Overview
  - 12.1.1.4.2 Iran: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.4.3 Iran: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
  - 12.1.1.4.4 Iran: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
  - 12.1.1.4.5 Iran: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
  - 12.1.1.4.6 Iran: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
  - 12.1.1.4.7 Iran: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
- 12.1.1.5 Turkey: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.5.1 Overview
  - 12.1.1.5.2 Turkey: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.5.3 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
  - 12.1.1.5.4 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
  - 12.1.1.5.5 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
  - 12.1.1.5.6 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
  - 12.1.1.5.7 Turkey: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
- 12.1.1.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.6.1 Overview
  - 12.1.1.6.2 Kuwait: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.6.3 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
  - 12.1.1.6.4 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
  - 12.1.1.6.5 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
  - 12.1.1.6.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
  - 12.1.1.6.7 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
- 12.1.1.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.7.1 Overview
  - 12.1.1.7.2 Bahrain: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.7.3 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
  - 12.1.1.7.4 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
  - 12.1.1.7.5 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
  - 12.1.1.7.6 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
  - 12.1.1.7.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
- 12.1.1.8 Egypt: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.8.1 Overview
  - 12.1.1.8.2 Egypt: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.8.3 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
  - 12.1.1.8.4 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
  - 12.1.1.8.5 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)
  - 12.1.1.8.6 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
  - 12.1.1.8.7 Egypt: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
- 12.1.1.9 Rest of Middle the East and Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.9.1 Overview
  - 12.1.1.9.2 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.9.3 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019-2028 (US\$ Million)
  - 12.1.1.9.4 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019-2028 (US\$ Million)
  - 12.1.1.9.5 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019-2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.1.1.9.6 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019-2028 (US\$ Million)
- 12.1.1.9.7 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019-2028 (US\$ Million)
- 13. Industry Landscape
  - 13.1 Overview
  - 13.2 Inorganic Growth Strategies
    - 13.2.1 Overview
  - 13.3 Organic Growth Strategies
    - 13.3.1 Overview
- 14. Company Profiles
  - 14.1 Merck & Co., Inc.
    - 14.1.1 Key Facts
    - 14.1.2 Business Description
    - 14.1.3 Products and Services
    - 14.1.4 Financial Overview
    - 14.1.5 SWOT Analysis
    - 14.1.6 Key Developments
  - 14.2 GlaxoSmithKline plc.
    - 14.2.1 Key Facts
    - 14.2.2 Business Description
    - 14.2.3 Products and Services
    - 14.2.4 Financial Overview
    - 14.2.5 SWOT Analysis
    - 14.2.6 Key Developments
  - 14.3 Serum Institute of India Pvt. Ltd
    - 14.3.1 Key Facts
    - 14.3.2 Business Description
    - 14.3.3 Products and Services
    - 14.3.4 Financial Overview
    - 14.3.5 SWOT Analysis
    - 14.3.6 Key Developments
  - 14.4 Walvax Biotechnology Co., Ltd.
    - 14.4.1 Key Facts
    - 14.4.2 Business Description
    - 14.4.3 Products and Services
    - 14.4.4 Financial Overview
    - 14.4.5 SWOT Analysis
    - 14.4.6 Key Developments
  - 14.5 Inovio Pharmaceuticals
    - 14.5.1 Key Facts
    - 14.5.2 Business Description
    - 14.5.3 Products and Services
    - 14.5.4 Financial Overview
    - 14.5.5 SWOT Analysis
    - 14.5.6 Key Developments
  - 14.6 Sanofi
    - 14.6.1 Key Facts
    - 14.6.2 Business Description

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 R-Pharm
  - 14.7.1 Key Facts
  - 14.7.2 Business Description
  - 14.7.3 Products and Services
  - 14.7.4 Financial Overview
  - 14.7.5 SWOT Analysis
  - 14.7.6 Key Developments
- 15. Appendix
  - 15.1 About The Insight Partners
  - 15.2 Glossary of Terms

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)**

Market Report | 2022-09-26 | 150 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>